JP2017061453A5 - - Google Patents

Download PDF

Info

Publication number
JP2017061453A5
JP2017061453A5 JP2016190522A JP2016190522A JP2017061453A5 JP 2017061453 A5 JP2017061453 A5 JP 2017061453A5 JP 2016190522 A JP2016190522 A JP 2016190522A JP 2016190522 A JP2016190522 A JP 2016190522A JP 2017061453 A5 JP2017061453 A5 JP 2017061453A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
composition according
relaxin
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016190522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017061453A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017061453A publication Critical patent/JP2017061453A/ja
Publication of JP2017061453A5 publication Critical patent/JP2017061453A5/ja
Pending legal-status Critical Current

Links

JP2016190522A 2008-05-16 2016-09-29 慢性心不全の治療方法 Pending JP2017061453A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014129744A Division JP2014237648A (ja) 2008-05-16 2014-06-25 慢性心不全の治療方法

Publications (2)

Publication Number Publication Date
JP2017061453A JP2017061453A (ja) 2017-03-30
JP2017061453A5 true JP2017061453A5 (cg-RX-API-DMAC10.html) 2017-07-13

Family

ID=41319370

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011509781A Withdrawn JP2011520917A (ja) 2008-05-16 2009-05-15 慢性心不全の治療方法
JP2014129744A Withdrawn JP2014237648A (ja) 2008-05-16 2014-06-25 慢性心不全の治療方法
JP2016190522A Pending JP2017061453A (ja) 2008-05-16 2016-09-29 慢性心不全の治療方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011509781A Withdrawn JP2011520917A (ja) 2008-05-16 2009-05-15 慢性心不全の治療方法
JP2014129744A Withdrawn JP2014237648A (ja) 2008-05-16 2014-06-25 慢性心不全の治療方法

Country Status (10)

Country Link
US (3) US20110144019A1 (cg-RX-API-DMAC10.html)
EP (2) EP3150219A1 (cg-RX-API-DMAC10.html)
JP (3) JP2011520917A (cg-RX-API-DMAC10.html)
CN (2) CN102026649A (cg-RX-API-DMAC10.html)
AU (1) AU2009246112B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0912559A2 (cg-RX-API-DMAC10.html)
CA (1) CA2724535A1 (cg-RX-API-DMAC10.html)
MX (2) MX336145B (cg-RX-API-DMAC10.html)
RU (1) RU2512933C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009140657A2 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
WO2012072681A1 (en) * 2010-12-01 2012-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Diagnostic and treatment of chronic heart failure
AU2012283235A1 (en) * 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US20140364334A1 (en) * 2011-12-21 2014-12-11 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
JP6562632B2 (ja) 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
NZ710246A (en) * 2013-01-25 2016-11-25 Cardiorentis Ltd Methods of treating cardiovasular indications
KR20160071472A (ko) * 2013-11-07 2016-06-21 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 릴렉신 유사체, 이의 약제학적 조성물 및 이의 약제학적 적용
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP3883591B1 (en) * 2018-11-20 2024-11-13 Universität Heidelberg Relaxin receptor 1 for use in treatment and prevention of heart failure
EP4058048A1 (en) * 2019-11-16 2022-09-21 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Medical composition for treating cardiac wasting and cachexia
CN116406297A (zh) * 2020-08-05 2023-07-07 阿斯克肋匹奥生物制药公司 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法
RU2748529C1 (ru) * 2020-09-01 2021-05-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения этиологии хронической сердечной недостаточности
IL321288A (en) * 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
CA2165781C (en) 1993-06-21 2007-02-13 Tim Breece Process for producing relaxin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
RU2213559C2 (ru) * 2000-01-26 2003-10-10 Тюменская государственная медицинская академия Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2007008907A2 (en) * 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin

Similar Documents

Publication Publication Date Title
Krell et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure
den Uil et al. Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial
JP2011520917A5 (cg-RX-API-DMAC10.html)
Szczepańska-Sadowska Hemodynamic effects of moderate increase of the plasma vasopressin level in conscious dogs
Carcillo et al. Goal-directed management of pediatric shock in the emergency department
US9314507B2 (en) Methods of treatment of heart failure with natriuretic peptides
RU2010151470A (ru) Способ лечения хронической сердечной недостаточности
López-Rivera et al. Treatment of hypertensive cardiogenic edema with intravenous high-dose nitroglycerin in a patient presenting with signs of respiratory failure: a case report and review of the literature
Jha et al. Vasoactive therapy in shock
Mills et al. “BNP” for heart failure: role of nesiritide in cardiovascular therapeutics
Simsic et al. Perioperative effects and safety of nesiritide following cardiac surgery in children
JP2016505065A5 (cg-RX-API-DMAC10.html)
Zineh et al. The evolving role of nesiritide in advanced or decompensated heart failure
Pensado et al. Haemodynamic effects of propofol during coronary artery bypass surgery
Sasaoka et al. Low dose carperitide (alpha-hANP) administration is effective for preventing worsening renal function (WRF) and long-term renal protection
Aundhakar et al. Cardiorenal syndrome: Resistant to diuretics, sensitive to ultraflitration
Rajapreyar et al. Novel pharmacotherapies for heart failure
Teerlink et al. Levosimendan reduces length of initial hospital stay: the REVIVE II study
Silver et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure
Lee et al. Forward blood flow provoked by changing intravascular pressure using an extracorporeal circulation during cardiopulmonary resuscitation.
Wang et al. Intravenous infusion of CXL-1020, a novel nitroxyl (HNO) donor, improves left ventricular systolic and diastolic function in dogs with advanced heart failure
Janwanishstaporn et al. The Relationship between LVEF and Cardiovascular Outcomes Following Hospitalization for Heart failure: Insights from the RELAX-AHF-2 Trial
Wittebole et al. High-dose insulin therapy in a case of subarachnoid hemorrhage-related severe cardiodepression with ischemic-like electrocardiographic changes
Solimando et al. Emerging Concepts in Acute Heart Failure: From the Pathophysiology to the Clinical Case Based Approach
Ghaffari et al. Pulmonary embolism in a patient with a rare coronary anomaly-a clue to the importance of proximal right coronary artery branches